AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
June 29, 2016- FDA also granted ibrutinib Orphan Drug Designation for this condition. There are currently no therapies specifically approved for cGVHD, a severe and potentially life-threatening condition in which transplanted cells from donor attack the patient's body
-
June 16, 2016
-
June 06, 2016- Findings from RESONATE™ (PCYC-1112), RESONATE™-2 (PCYC-1115), and HELIOS (CLL3001) studies. This press release corresponds to abstracts #7525 and #7520.
-
June 05, 2016- Results of expansion cohort of open-label Phase 1 study found no dose-limiting toxicities and frequent, reversible eye toxicities
-
June 05, 2016- Secondary objective demonstrated one-year overall survival rate in 32 percent of patients identified with high expression of delta-like protein 3 (DLL3) SCLC
-
June 03, 2016- AbbVie is dedicated to delivering innovative new therapies that significantly advance the standard of care
-
June 02, 2016- Twenty-six presentations evaluate either HUMIRA, investigational treatments or related topics in multiple autoimmune diseases
-
May 31, 2016- This decision follows April 29 recommendation from the Committee for Medicinal Products for Human Use (CHMP) in the EU in favor of approval
-
May 27, 2016Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple SclerosisApproval Supported by Largest and Longest Head-to-Head Phase 3 Study Conducted in Multiple Sclerosis (MS)
-
May 27, 2016- If approved by the European Commission, HUMIRA would be the first biologic treatment option in the European Union for certain patients with non-infectious intermediate, posterior and panuveitis
-
May 24, 2016- After 12 weeks, approximately twice as many patients with moderate-to-severe Crohn's disease, the majority of whom had previously failed treatment with one or more TNF antagonists, achieved clinical remission with risankizumab compared with placebo(1)
-
May 19, 2016- Data presentations further evaluate HUMIRA® (adalimumab) for the treatment of inflammatory bowel diseases including moderate to severe Crohn's disease in adult and pediatric patients
-
May 18, 2016- New data to be presented from clinical trials evaluating Venclexta™ (venetoclax) and IMBRUVICA® (ibrutinib)
-
May 09, 2016- Update to the IMBRUVICA U.S. Prescribing Information includes overall survival data from RESONATETM-2 study show significant improvements in previously untreated CLL/SLL patients with IMBRUVICA compared to chemotherapy (chlorambucil)
-
April 29, 2016- Recommendation follows recent approval by the U.S. FDA for this indication
-
April 28, 2016- Reports First-Quarter Adjusted Diluted EPS of $1.15, Up 22.3 Percent; GAAP Diluted EPS of $0.83
-
April 28, 2016- Rovalpituzumab tesirine (Rova-T) is a biomarker-specific antibody drug conjugate targeting cancer stem cell protein DLL3
-
April 25, 2016- Approval supported by TURQUOISE-III study showing 100 percent SVR12 (N=60/60) in chronic hepatitis C virus (HCV) infected genotype 1b patients with compensated cirrhosis (Child-Pugh A)
-
April 21, 2016- Companies to Jointly Develop and Commercialize Probody Drug Conjugates Directed Against CD71
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
